Purpose The utility of perfusion-weighted imaging in multiple sclerosis (MS) is not well investigated. The purpose of this study was to compare baseline normalized perfusion measures in subgroups of newly diagnosed MS patients. We wanted to test the hypothesis that this method can differentiate between groups defined according to disease severity and disease activity at 1 year follow-up. Methods Baseline magnetic resonance imaging (MRI) including a dynamic susceptibility contrast perfusion sequence was performed on a 1.5-T scanner in 66 patients newly diagnosed with relapsing-remitting MS. From the baseline MRI, cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT) maps were generated. Normalized (n) perfusion values were calculated by dividing each perfusion parameter obtained in white matter lesions by the same parameter obtained in normal-appearing white matter. Neurological examination was performed at baseline and at follow-up approximately 1 year later to establish the multiple sclerosis severity score (MSSS) and evidence of disease activity (EDA). Results Baseline normalized mean transit time (nMTT) was lower in patients with MSSS >3.79 (p = 0.016), in patients with EDA (p = 0.041), and in patients with both MSSS >3.79 and EDA (p = 0.032) at 1-year follow-up. Baseline normalized cerebral blood flow and normalized cerebral blood volume did not differ between these groups. Conclusion Lower baseline nMTT was associated with higher disease severity and with presence of disease activity 1 year later in newly diagnosed MS patients. Further longitudinal studies are needed to confirm whether baseline-normalized perfusion measures can differentiate between disease severity and disease activity subgroups over time.
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Introduction
Multiple sclerosis (MS) is an important cause of neurological disability in young adults [1] . The disease varies in terms of severity, and both disease progression and disease activity are difficult to predict at onset [2] [3] [4] [5] . Imaging biomarkers that could help in early identification of patients at risk of developing a severe disease course would be a useful tool in clinical management. There have been several attempts to grade disease severity in MS and to identify prognostic parameters for benign and severe disease course, including volumetric measures [6] [7] [8] [9] [10] . To date, no such parameters have been validated. To assess disease severity in MS at a single time point, the MS severity score (MSSS) can be used. MSSS describes disease severity as neurological disability in relation to disease duration, and has been proven useful for comparing groups of patients [11] . Disease activity can be assessed using the concept of evidence of disease activity (EDA), based on a composite of clinical and radiological measures. The concept was recently introduced in clinical trials where the absence of EDA, no evidence of disease activity (NEDA), was used as an outcome measure in evaluation of diseasemodifying treatments (DMTs) [12] [13] [14] .
Magnetic resonance imaging (MRI) is an important tool in diagnosis and follow-up of MS patients [15] [16] [17] . Furthermore, advanced MRI has shown promising results in establishing prognosis and in disease monitoring in MS, but it is still not well explored and a need for new MRI markers has been highlighted [10] . One advanced MRI technique is dynamic susceptibility contrast perfusionweighted imaging (PWI) that enables measurement of cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT) in brain tissue [18] . Due to known large technical and biological variations in these perfusion measures, only normalized perfusion values can reliably be compared across individuals [19] , calculated as the ratio of a perfusion measure from two different brain regions in the same subject. Such normalization has been extensively used in neurooncology [20, 21] and cerebral ischemic disease [22] , while in MS, it has been used, e.g., for assessment of perfusion in lesions normalized to contralateral normal-appearing white matter (NAWM) [23] or for analyzing the association between clinical data and perfusion in different brain regions normalized to hippocampi [24] . There is some literature describing PWI findings in relation to clinical data in patients with MS [24] [25] [26] [27] , but, to our knowledge, there are no previous reports exploring normalized perfusion measures in relation to disease severity and activity in MS.
This study is based on perfusion data from our previous baseline study [28] and on clinical data from approximately 1-year follow-up [29] . We aimed to investigate whether there are differences in normalized perfusion measures between clinical subgroups of newly diagnosed MS patients, defined according to disease severity and disease activity. We hypothesized that patients with higher severity (higher MSSS scores), with active disease (presence of EDA), and with both higher severity and active disease 1 year later differ in their baselinenormalized perfusion measures from patients with a more benign disease course.
Materials and methods

Subjects
Sixty-six patients newly diagnosed with relapsing-remitting (RR) MS according to the revised 2010 McDonald criteria [17] were prospectively enrolled in this study. The patients were diagnosed with MS between January 2009 and October 2012, and recruited from an on-going longitudinal study at our institution [29] . All patients underwent a detailed neurological examination at baseline within 14.4 ± 9.6 months (range 1-34) from diagnosis. The baseline MRI scan was acquired within a week from the baseline neurological examination. The follow-up neurological examination and the follow-up MRI scan were repeated approximately 1 year later (on average 14 ± 1.7 months). The inclusion criteria at baseline were as follows: age 18-50 years; no more than 3 years since MS diagnosis; at least 6 weeks since the last relapse or steroid treatment; no prior neurological, neurovascular, or psychiatric disease; and no substantial head injury or drug abuse. The exclusion criteria were as follows: pregnancy or breastfeeding, previous adverse reaction to gadolinium injection, and inadequate image quality on MRI scans. The following demographical and clinical measures were obtained in all patients at baseline: age, sex, age at disease onset, time since diagnosis, disease duration, neurological disability as measured by expanded disability status scale (EDSS) [30] , number of relapses, and use of DMT. MSSS was calculated based on EDSS and disease duration. At baseline, 68% of the patients received first-line DMT, 14% received second-line DMT and 18% no DMT. At follow-up, the EDSS was reassessed, the MSSS was calculated, the number of new relapses was recorded, and the EDA/NEDA status was determined based on the clinical and radiological progression as previously published [29] . The clinical data could not be obtained in one patient at follow-up. The characteristics of the patient cohort are presented in Table 1 (A).
Image acquisition
MRI scanning was performed as baseline on the same 1.5-T scanner (Avanto, Siemens Medical, Erlangen, Germany) equipped with a 12-channel head coil. The following sequences were acquired: 
Image processing
Details concerning image processing are given in a previous perfusion study at our institution that used the same patient material [28] . The perfusion data were processed with the nordicICE software package (www.nordicneurolab.com), resulting in CBF, CBV, and MTT perfusion parametric maps ( Fig. 1) . A population-based average arterial input function was used in the perfusion analysis. Correction for partial volume effects (PVEs) was not specifically performed due to lack of established methods for this purpose. Proper PVE Disease duration at baseline (months) 21 Time between baseline and follow-up (months) 14.0 ± 1.7
Neurological disability by EDSS at follow-up (n = 65) 2.0 (1.5-2. EDA evidence of disease activity, EDSS expanded disability status scale, MRI magnetic resonance imaging, MS multiple sclerosis, MSSS multiple sclerosis severity scale, nCBF normalized cerebral blood flow, nCBV normalized cerebral blood volume, nMTT normalized mean transit time, WML white matter lesions a Disease-modifying treatment: first line: interferon, glatiramer acetate, teriflunomide, and dimethyl fumarate; second line: natalizumab, fingolimod, and alemtuzumab b Normalized perfusion measures calculated as perfusion parameters obtained in WML divided by the same parameters obtained in normalappearing white matter c Normalized to intracranial volume d Based on manually corrected WML mask coregistered to perfusion maps correction would require knowledge of the point spread function of the perfusion sequence [31] , which is not easily obtainable for echo planar imaging sequences. We attempted to reduce PVE by down-sampling the high-resolution lesion mask to perfusion space, thereby avoiding any detrimental re-slicing of the low-resolution perfusion images. In the perfusion analysis, the parameters were adjusted to minimize the influence of the residual leakage. Leakage correction was performed using an established algorithm [32] . The algorithm uses linear fitting to estimate the T1 contamination caused by contrast agent extravasation, and by removing the leakage term, it allows generation of corrected perfusion maps.
Binary masks of white matter (WM) and gray matter (GM) were created from the volumetric T1 series using the Matlabbased Statistical Parametric Mapping toolbox (SPM8; http:// www.fil.ion.ucl.ac.uk/spm). Volumetric measures and white matter lesion (WML) masks were generated automatically from the 3D T1 and FLAIR series using the CASCADE software (ki.se/en/nvs/cascade, Karolinska Institute, Stockholm, Sweden) [33] . The volumetric measures were normalized to intracranial volume. The structural series and the binary masks were coregistered to the perfusion maps using SPM8. The coregistered WML masks were visually inspected and edited in nordicICE software by a neuroradiologist to control for errors in the automatic lesion detection. The editing was performed by adding the automatically generated lesion segments as overlays on anatomical FLAIR series, which allowed adding and removing pixels from the WML mask. This correction provided quality control for the final WML masks. Dice similarity coefficient was calculated for the original and the edited WML masks. Region-of-interest analysis was performed to extract perfusion parameters corresponding to the WML and NAWM masks. Normalized (n) perfusion measures were calculated by dividing each perfusion parameter obtained from the whole volume of WML by the same parameter obtained from the whole volume of NAWM. As a result, normalized cerebral blood flow (nCBF), normalized cerebral blood volume (nCBV), and normalized mean transit time (nMTT) values were calculated for each patient. Normalization to the whole NAWM was chosen due to easy reproducibility and availability of whole WM segmentation methods and because previous reports showed that changes in NAWM in MS are general and found in both infra-and supratentorial WM with diffusion tensor imaging [34] . Figure 2 shows WML and NAWM masks overlaid on a MTT perfusion map in a sample patient. In addition, the coregistered WML masks were post-processed using inhouse software developed in Matlab R2012a (MathWorks, Natick, MA, USA) to obtain lesion count.
There were only seven contrast-enhancing lesions in our material (one lesion each in seven patients), probably due to the fact that the patients were clinically stable when they came for scanning. In our study, we wanted to focus on perfusion properties of the whole volume of lesions, but a separate analysis of the contrast-enhancing lesions was performed by us previously [28] . The analysis showed no difference in perfusion parameters between the enhancing and the nonenhancing lesions (p = 0.414, p = 0.904, and p = 0.332 for CBV, CBF, and MTT, respectively). For this reason, all lesions were included in the final analysis. 
Statistical analysis
The Statistical Package for the Social Sciences software (SPSS v22, IBM, Chicago IL, USA) was used for all statistical analyses. Since the tested normalized perfusion parameters and volumetric measures were normally distributed in the Kolmogorov-Smirnov normality test, the parametric oneway between-group analysis of covariance (ANCOVA) test was used for group analysis. Since we previously have shown that the EDA patients included in this study cohort used more first-line treatment and less second-line treatment than NEDA patients [29] , all the group comparisons were performed with disease-modifying treatment (DMT) as covariate, to control for possible influence of DMT on the results. Analyses of volumetric parameters were controlled for DMT and for age. All reported p values are two-sided, and the significance level was set to 0.05.
Results
Clinical characteristics
Mean age of the patients at baseline was 34.9 ± 7.2 years, female/male ratio was 2:1, mean age at disease onset was 32.6 ± 6.7 years, median disease duration to baseline MRI was 21 months (range 3-128), and mean time from diagnosis to baseline MRI was 14.4 ± 9.6 months ( Table 1 (A)). MSSS was 4.22 ± 1.99 (n = 65) at follow-up. The patients were divided in clinical groups according to disease severity measured by MSSS and according to EDA/ NEDA status at follow-up. EDA status was found in 30 (46%) patients.
Imaging findings
The imaging characteristics and volumetric measures are shown in details in Table 1 (B). Mean nMTT was 1.27 ± 0.15. Mean brain volume normalized to intracranial volume was 0.81 ± 0.20. Mean lesion count was 20 ± 14 per patient. Contrast-enhancing lesions were observed in seven patients only (one lesion in each patient), representing 0.5% of all 1347 lesions detected. Median total pixel number of the automatically generated WML mask (registered to perfusion maps) was 323 (range 128-1178), median total pixel number of the edited WML mask was 186 (range 24-1319), and mean Dice similarity coefficient between these masks was 0.51 ± 0.24. Median absolute MTT values are given in Supplementary Table 1 .
Group comparisons
Demographical and clinical characteristics of the groups
The definitions of the groups are described in details in the following in each comparison. The proportion of females was different in NEDA group compared to EDA group and different in group with MSSS ≤ 3.79 and NEDA compared to group with MSSS >3.79 and EDA. Mean age was different in group with MSSS ≤ 3.79 compared to group with MSSS >3.79 (Table 2) .
Comparison of groups defined according to disease severity by MSSS at follow-up
Since benign MS is usually defined as EDSS of three or less at least 10 years from disease onset [6] [7] [8] , we defined the group with higher disease severity as patients with MSSS >3.79 (equivalent to EDSS >3.0 at 10 years of disease duration) and lower severity group as patients with MSSS ≤3.79 (equivalent to EDSS ≤3.0 at 10 years of disease duration). The nMTT was lower (ANCOVA: p = 0.016, F(1,62) = 6.12, η 2 = 0.09) in patients with higher severity (n = 36) compared to patients with lower severity (n = 29) while nCBF and nCBV did not differ between the groups (Table 3 (A) and Fig. 3a) . The baseline whole-brain volume was lower (ANCOVA: p = 0.043, F(1,62) = 4.28, η 2 = 0.07) in patients with higher severity while GM and WM volumes showed no difference between the MSSS groups (Table 4 (A) ).
Comparison of groups defined according to disease activity by EDA/NEDA status
The participants were grouped according to disease activity as defined by their EDA/NEDA status established at 1-year follow-up in a previous clinical study in the same cohort [29] (EDA was defined as a presence of at least one of the following: disability progression, new relapse(s), or radiological progression). Only nMTT differed depending on the EDA/NEDA status: it was lower (ANCOVA: p = 0.041, F(1,62) = 4.35, η 2 = 0.07) in the EDA group (n = 30) compared to the NEDA group (n = 35), while nCBF and nCBV were similar in both groups (Table 3 (B) and Fig. 3b) . The volumetric measurements showed no difference in this comparison (Table 4 
(B)).
Comparison of groups defined according to disease severity by both MSSS and EDA/NEDA status at follow-up In this analysis, the patients were divided in two groups according both to their disease severity as measured by MSSS and disease activity defined by EDA/NEDA status. One group was defined as patients with more severe disease course (follow-up MSSS >3.79 and EDA) and the other group as patients with more benign disease course (follow-up MSSS ≤3.79 and NEDA). The nMTT was significantly lower in the more severe group (n = 21) compared to the more benign group (n = 44) after controlling for age and DMT (ANCOVA: p = 0.032, F(1,62) = 4.81, η 2 = 0.07) while nCBF and nCBV were similar (Table 3 (C) and Fig. 3c) . Hence, nMTT was lower in the less benign group regardless of whether patients were grouped according to MSSS and EDA/NEDA status alone or according to both. The volumetric measurements were similar in this comparison (Table 4 (C)).
Discussion
In this prospective longitudinal study of newly diagnosed MS patients, we found that baseline nMTT was significantly lower in patients with higher disease severity as assessed by MSSS at 1-year follow-up. These results suggest that the baseline microvascular properties of MS lesions (related to NAWM) in newly diagnosed MS patients differ with future disease development. Previous studies have revealed heterogeneity of histopathological changes in MS [35] [36] [37] . There is ongoing debate about different mechanisms of demyelination [36, 38] . Perivascular T cell infiltration and microglia activation are widespread in many MS patients as well as scattered parenchymal T cell infiltration, also in the chronic disease phase [39] . These findings are also supported in a previous study by Adams et al. [40] who found lymphocytic perivascular Table 3 Baseline-normalized perfusion measures in patient groups defined according to disease severity by MSSS (A), disease activity by EDA/ NEDA status (B), and both disease severity and activity (C) at 1-year follow-up, n = 65 EDA evidence of disease activity, GM gray matter, MSSS multiple sclerosis severity score, nCBF normalized cerebral blood flow, nCBV normalized cerebral blood volume, NEDA no evidence of disease activity, nMTT normalized mean transit time a One-way analysis of covariance (ANCOVA), controlled for disease-modifying treatment. p values < 0.05 are indicated with italics infiltration, lesion hypercellularity, and macrophage infiltration in MS lesions. In general, little is reported about vascular changes associated with MS lesions. Lesions in MS tend to be in perivenular locations [41] . Lassmann et al. [39] reported that disturbances of the microcirculation due to focal edema within inflammatory lesions, inflammatory reaction of the vessel wall resulting in microvascular thrombosis, or endothelial damage by T lymphocytes are possible mechanisms of demyelination in some patients. An increased density of microvessels has also been reported by the authors. All these factors may influence perfusion parameters in MS patients. It is therefore plausible that vascular properties of both the WML and NAWM in MS patients can vary across individuals depending on vascular involvement in the pathological changes. In our study from 2015, we reported reduced perfusion in WML compared to NAWM in MS patients [28] . Thus, lower nMTT in patients with higher disease severity can be interpreted as less reduced (or relatively increased) WML perfusion, which might be caused by different patterns of vascular or perivascular affection in these patients, compared to the Table 4 Baseline volumetric data in patient groups defined according to disease severity by MSSS (A), disease activity by EDA/NEDA status (B), and both disease severity and activity (C) at 1-year follow-up, n = 65
A. Groups defined according to disease severity by MSSS MSSS ≤3.79 n = 29 MSSS >3.79 n = 36 F, partial η patient group with lower disease severity. Alternatively, this finding could also indicate predominating changes in NAWM (relatively reduced perfusion in NAWM compared to WML). Furthermore, the nMTT differed significantly between groups defined according to disease activity: it was lower in the EDA group where disease activity was present at 1-year follow-up and in the group defined as patients with both higher disease severity and EDA at follow-up. The fact that higher severity (determined by MSSS) and presence of activity (determined by EDA/NEDA status) were both associated with lower nMTT suggests a similar biological explanation. Interestingly, observed variations in nMTT in our study were not accompanied by a corresponding variation in nCBV or nCBF. This may seem surprising, given that MTT is defined as the ratio CBV/CBF [18] . However, nCBV and nCBF are estimated globally from the ratio of mean values in WML and NAWM whereas MTT is estimated pixel-wise prior to normalization. Hence, nMTT may reveal variations, not reflected in the global nCBV and nCBF measures.
Although only normalized values should be compared between patient groups, we performed additional analysis of absolute MTT values in NAWM and WML between the patient groups to see which region, NAWM or WML, influences the normalized MTT values. This analysis suggested that the nMTT results between MSSS groups are driven mainly by changes in WML (p = 0.048) and between the EDA/NEDA groups are driven mainly by changes in NAWM (p = 0.025). The detailed absolute MTT values in the groups are shown in supplementary Table 1 . These results should be interpreted with caution as we cannot estimate the influence of physiologically and technically related variations.
The baseline total brain volume was significantly lower in patients with higher severity. This finding is partly in line with previous research reports where whole-brain atrophy [42] and baseline GM volumes [43, 44] were associated with disease severity in MS. No volumetric measures showed significant difference between groups defined according to disease activity (determined by EDA/ NEDA status) in our study. In our analyses, the nMTT showed more significant results than atrophy measurements in all performed comparisons.
Our finding of no difference in perfusion measures between enhancing and non-enhancing lesions may seem surprising but it is at least partly supported by a previous study from 2005 [23] where non-enhancing lesions referred to as class 2 were not distinguishable from enhancing lesions in their perfusion properties. In our material, because of a very low number of enhancing lesions (7 of all 1347 lesions detected), the contribution of these lesions to perfusion values would be negligible. Dice similarity coefficient between the original and the edited WML masks was low (0.51 ± 0.24), which confirms that modification of the original mask (visual inspection and editing) was necessary.
The strengths of the study are that the patients underwent a detailed neurological examination as previously described [29, 45] . The patients were newly diagnosed and are followed longitudinally. The number of participants is relatively large compared to other published perfusion studies in MS which typically included not more than 45 subjects [25] [26] [27] . We used a semiautomated image processing method for creating binary masks; this is an advantage as it minimizes the user bias. The perfusion sequence is not time-consuming and does not require more intravenous contrast than the standard dose routinely used in MS. Thus this sequence can easily be added to the scanning protocol without increasing scan length with more than 2 min. Our approach in the perfusion analysis (use of normalized perfusion measures, not absolute values) provides reliability for comparisons across subjects, which is also strength of the study.
The main limitation of the study is a short observation time which was 14 months on average. A longer follow-up time is interesting as it would increase the usefulness of the perfusion sequence if it proves to be associated with clinical findings even after 2-3 years or more. Another limitation is that the MRI acquisition was on a 1.5-T scanner; this gives a lower signal-to-noise ratio compared to 3.0 T and may have influenced our results. Our method that required use of lesion segmentation and perfusion analysis may seem time-consuming, but these techniques are under constant development, and even today, they are not more complicated than atrophy measurements; moreover, some neuroradiology departments use perfusion techniques routinely, and are familiar with these analyses. Normalization to NAWM in a disease of the whole brain can be questioned, but since the cohort of this study consists of newly diagnosed patients who have not yet reached the progressive phase, it can be assumed that pathological changes in NAWM would be subtle in these patients [37] . In addition, a newer perfusion study has suggested normal perfusion in NAWM in MS patients compared to healthy controls [46] .
In conclusion, lower baseline nMTT was associated with higher disease severity and with presence of disease activity 1 year later in newly diagnosed MS patients. This study suggests that MRI perfusion parameters are promising as imaging biomarkers of disease severity and activity in MS, but there is a need for further longitudinal research.
